PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI's platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/04/19 | $75,000,000 | Series B |
Bristol-Myers Squibb General Atlantic  LabCorp Merck Global Health Innovation Fund | undisclosed |
